Licofelone - Clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis

Rheumatology

Volumn 43, Issue SUPPL. 1, 2004, Pages

  Alvaro Gracia, J M ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

5 LOX; Celecoxib; COX 2; COX1; Licofelone; LOX COX inhibitor; NSAIDs; Safety

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; LEUKOTRIENE; LICOFELONE; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ABDOMINAL PAIN; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING COMPETITION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPY; FLATULENCE; GASTRODUODENAL ULCER; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; INCIDENCE; NAUSEA AND VOMITING; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; STOMACH ULCER; SYMPTOMATOLOGY; VOLUNTEER;

ACETIC ACIDS; ARACHIDONATE 5-LIPOXYGENASE; ASPIRIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG COMBINATIONS; GASTROINTESTINAL DISEASES; HUMANS; ISOENZYMES; LIPOXYGENASE INHIBITORS; LONG-TERM CARE; MEMBRANE PROTEINS; OSTEOARTHRITIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; PYRROLES; SULFONAMIDES;

EID: 1242342177     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Simon LS, Lanza FL, Lipsky PE et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-602.
2. Komers R, Anderson S, Epstein M. Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. Am J Kidney Dis 2001;38:1145-57.
3. Mengle-Gaw LJ, Schwartz BD. Cyclooxygenase-2 inhibitors: promise or peril? Mediators Inflamm 2002;11:275-86.
4. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340: 1888-99.
5. Ma L, del Soldato P, Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci USA 2002;99:13243-7.
6. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2003;62: 501-9.
7. Celotti F, Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol Res 2001;43:429-36.
8. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997;112:1000-1-6.
9. Tries S, Neupert W, Laufer S. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 2002;51:135-43.
10. Tries S, Laufer S. Pharmacological profile of ML3000: a new gastric mucosa sparing anti-inflammatory drug with COX/5-LOX inhibitory activity. Inflamm Res 2001;50:S187.
11. Laufer S. Discovery and development of ML3000. Inflammopharmacology 2001;9:101-12.
12. Algate DR, Augustin J, Atterson PR et al. General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1 H-pyrrolozine-5-yl]-acetic acid in experimental animals. Arzneimittelforschung 1995;45:159-65.
13. Wallace JL, Carter L, McKnight W, Tries S, Laufer S. ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury. Eur J Pharmacol 1994;271:525-31.
14. Laufer S, Tries S, Augustin J, Dannhardt G. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Arzneimittelforschung 1994;44:629-36.
15. Laufer S, Tries S, Augustin J et al. Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H -pyrrolizine-5-yl]-acetic acid. Arzneimittelforschung 1995;45:27-32.
16. Laufer S, Tries S, Augustin J et al. Gastrointestinal tolerance of [2,2-dimethyl-6-(4-chlorophenyl-7-phenyl-2,3-dihydro-1H -pyrrolizine-5-yl]-acetic acid in the rat. Arzneimittelforschung 1994;44: 1329-33.
17. Klesser B, Bias P, Buchner A. Licofelone (ML3000), an inhibitor of COX-1, COX-2 and 5-LOX, has little or no effect on the gastric mucosa after 4 weeks of treatment. Ann Rheum Dis 2002;61(Suppl. 1) 130 (Abstract THU0243).
18. Roth SH, Tindall EA, Jain AK et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993;153:2565-71.
19. Roth SH, Bennett RE, Caldron PH. Endoscopic evaluation of the long term effects of diclofenac sodium and naproxen in elderly patients with arthritis. Clin Drug Invest 1995;9:171-9.
20. Taha AS, Hudson N, Hawkey CJ et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996;334:1435-9.
21. Cheatum DE, Arvanitakis C, Gumpel M, Stead H, Geis GS. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther 1999;21:992-1003.
22. Bias P, Buchner A. Licofelone-a 5-LOX, COX-1 and COX-2 inhibitor-is as effective as naproxen and has improved GI tolerability in patients with osteoarthritis. Arthritis Rheum 2003;48(Suppl.):S72 (Abstract 68).
23. Blanco F, Buchner A, Bias P, Lammerich A, Schulz U. Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, is as effective as naproxen and shows improved safety during 12 months of treatment in patients with osteoarthritis of the knee. Ann Rheum Dis 2003;62(Suppl. 1):262 (Abstract FRI0217).
24. Pavelka K, Bias P, Buchner A, Lammerich A, Schulz U. Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, is as effective as celecoxib and shows improved tolerability during 12 weeks of treatment in patients with OA of the knee. Ann Rheum Dis 2003;62(Suppl. 1):261 (Abstract FRI0215).
25. Simon LS, Smolen JS, Abramson SB et al. Controversies in COX-2 selective inhibition. J Rheumatol 2002;29:1501-10.
26. Cheng HF, Harris RC. Does cyclooxygenase-2 affect blood pressure? Curr Hypertens Rep 2003;5:87-92.
27. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
28. Goldstein JL, Correa P, Zhao WW et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019-27.
29. Fiorucci S, Distrutti E, de Lima OM et al. Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J 2003;17:1171-3.
30. Bias P, Buchner A. Licofelone - an inhibitor of 5-LOX, COX-1 and COX-2 has superior GI tolerability in OA patients compared with naproxen, regardless of low-dose aspirin co-medication, previous ulcer history or H. pylori status. Arthritis Rheum 2003;48(Suppl.):S72 (Abstract 67).